e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
New bronchodilators for COPD management
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study
J. Beier, A. M. Kirsten, R. Mroz, R. Segarra, F. Chuecos, C. Caracta, E. Garcia Gil (Wiesbaden, Grosshansdorf, Germany; Bialystok, Poland; Barcelona, Spain; Jersey City, United States Of America)
Source:
Annual Congress 2013 –New bronchodilators for COPD management
Session:
New bronchodilators for COPD management
Session type:
Oral Presentation
Number:
184
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Beier, A. M. Kirsten, R. Mroz, R. Segarra, F. Chuecos, C. Caracta, E. Garcia Gil (Wiesbaden, Grosshansdorf, Germany; Bialystok, Poland; Barcelona, Spain; Jersey City, United States Of America). Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study. Eur Respir J 2013; 42: Suppl. 57, 184
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: A phase IIIb study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Effect of glycopyrronium vs tiotropium on pulmonary function and morning symptoms in patients with moderate-to-severe COPD: The SPRING study
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
The effect of twice-daily aclidinium bromide on cough and sputum in patients with COPD: Results from phase III studies
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Efficacy and safety of extrafine glycopyrronium bromide pMDI (CHF 5259) in COPD patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Sleep architecture in COPD patients during salmeterol
versus
tiotropium bromide treatment
Source: Eur Respir J 2006; 28: Suppl. 50, 199s
Year: 2006
Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
ACCORD COPD I: Twice-daily aclidinium bromide improves quality of life and dyspnea in COPD patients
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
Source: Eur Respir J 2012; 40: 1106-1114
Year: 2012
Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice-daily aclidinium bromide
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011
QVA149 showed significant improvements in lung function and health status and was well tolerated versus glycopyrronium and tiotropium in patients with severe COPD: The SPARK study
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
AMPLIFY: efficacy of aclidinium vs tiotropium in COPD
Source: International Congress 2018 – COPD management
Year: 2018
TIOSPIR®: Large scale trial of tiotropium Respimat® vs HandiHaler® (HH) in patients (pts) with COPD
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Clinically important deterioration in patients with COPD using umeclidinium/vilanterol, tiotropium or placebo: Pooled data
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept